Posterior reversible encephalopathy syndrome due to combination vemurafenib and cobimetinib for metastatic melanoma

Abstract

The combination of BRAF and MEK inhibitors has improved the prognosis of patients with BRAFV600-mutated metastatic melanoma (Larkin et al., 2014). The toxicity profiles of these drugs are mostly defined by gastrointestinal events, photosensitivity, hepatitis, and arthralgia (Larkin et al., 2014). We report a case of posterior reversible encephalopathy syndrome (PRES) induced by vemurafenib and cobimetinib.

A 68-year-old man, with neither a medical history nor any treatment, was surgically treated in November 2015 for stage IIB chest melanoma (superficial-spreading melanoma, Breslow 7 mm, with a high mitotic rate and without ulceration).

This article is protected by copyright. All rights reserved.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2gb1gh5
via IFTTT